Category: Lymphoma News

Clinical Trial Available for Untreated DLBCL

Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)

Update: this study is closed to enrollment. 

Although many patients with diffuse large B cell lymphoma are cured with initial treatment, some patients do not respond well to therapy, or they relapse after an initial response. Certain factors have been shown to predict the probability of responding well, but they are not able to define whether an individual patient will respond well to treatment.

In this study, we are examining the ability of FDG-PET scanning early on in treatment to predict the ultimate outcome of that treatment in an individual patient. We hope to use the information gained in this study to individualize treatment in the future.

Key eligibility:

  • Diagnosis of CD20+ diffuse large B-cell lymphoma (DLBCL) of any stage, including subtypes:
  • Mediastinal large B-cell
  • Centroblastic
  • Immunoblastic
  • T-cell rich B-cellmed
  • Anaplastic B-cell lymphoma
  • No prior anti-lymphoma therapy

Click here for a more detailed description of this study or contact June Greenberg, RN at (212) 746-2651 or jdg2002@med.cornell.edu.

Dr. Rebecca Elstrom Discusses Indolent Lymphoma

Weill Cornell’s Rebecca Elstrom, MD was interviewed for the Lymphoma Foundation of America’s Lymphoma Help webcast series. Dr. Elstrom discussed Indolent Lymphomas. Click the player below to listen to the discussion with Dr. Elstrom.

Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies

Update: this study is closed to enrollment. 

Previous expericence with antibody therapy in both non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) suggests the need for further exploration of new antibody treatments for these diseases.

This is a Phase I, open-label study being conducted in patients with recurrent non-Hodgkin’s lymphoma or chronic lymphocytic leukemia who have progressed after at least one prior standard treatment.

Click here to for the clinical and research profile of John Leonard, MD, the physician leading the study.